Liquid Biopsy Assays: Beyond Recurrence Detection in Post-Diagnosis Cancer Management

Life Sciences, Clinical Trials, Drug Discovery & Development, Biomarkers,
  • Friday, December 02, 2022

MRD is rapidly emerging as a key biomarker in therapy development and patient care, however, key challenges remain. Personalis is committed to addressing some of the most pressing needs in the liquid biopsy space.

In this webinar attendees will learn about the role of next-generation liquid biopsy assays in enabling:

  • Earlier detection of disease recurrence
  • Utility in more disease indications, and at earlier stages of disease
  • Patient enrichment, screening/enrollment and surrogate endpoint analysis for clinical trials
  • Higher resolution variant tracking
  • Combining plasma and tissue analyses

Register to learn how liquid biopsy assays go beyond recurrence detection in post-diagnosis cancer management.

Speaker

http://Dan%20Norton,%20Personalis%20Inc.

Dan Norton, Associate Director, Product Management, Personalis Inc.

Dan Norton is currently Associate Director of Product Management with a focus on liquid biopsies at Personalis, following a role as Senior Product Manager focused on immuno-oncology. Prior to this, Dan had several product management and business development roles at Bio-Rad Laboratories, Illumina, Althea Technologies and Bayer Healthcare. Dan has an MBA from University California, San Diego and a BS from University California, Los Angeles.

Message Presenter

Who Should Attend?

Professionals from biopharmaceutical organizations with cancer drug pipelines working within:

  • Immuno-Oncology Clinical Development Programs
  • Clinical Program Managers or Project Managers
  • Biomarker and CDx Laboratory Directors and Scientists
  • Chief Medical and Scientific Officers
  • Bioinformatics and Genomics
  • Medical Affairs
  • Procurement

Who want to better understand how to leverage comprehensive immunogenomic sequencing of clinical trial samples, using both tissue and liquid biopsy, to help drive biomarker discovery and drug development programs.

What You Will Learn

Attendees will learn how next-generation liquid biopsy assays can enable:

  • Earlier detection of disease recurrence
  • Utility in more disease indications, and at earlier stages of disease
  • Patient enrichment, screening/enrollment and surrogate endpoint analysis for clinical trials
  • Higher resolution variant tracking
  • Combining plasma and tissue analyses

Xtalks Partner

Personalis

Personalis, Inc. is leading the oncology field in developing patient-centered diagnostics by delivering tumor-informed comprehensive insights. The Personalis NeXT Platform® and suite of products are designed to capture the complex and evolving understanding of cancer, providing biopharmaceutical partners and clinicians with information on 20,000 human genes and the immune system from a single tissue sample.

With NeXT PersonalTM these insights are expanded into a tumor-informed, ultra-sensitive ctDNA analysis, enabling earlier detection of disease recurrence (MRD) in a broader range of indications at earlier stages. Personalis operates a CAP/CLIA-accredited laboratory in the United States, delivering our NeXT DxTM test, a comprehensive genomic testing solution that enables physicians to identify potential targeted and/or immunotherapy options, evidence of drug resistance and clinical trial options for patients with solid tumors. Personalis also operates a Wholly Foreign-Owned Enterprise and laboratory in China, with HGRAC approval of NeXT Platform to provide retrospective testing in clinical trials.

You Must Login To Register for this Free Webinar

Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.

Create Account